Henry Schein, Inc. (NASDAQ:HSIC) saw unusually large options trading on Tuesday. Stock traders bought 4,098 put options on the company. This is an increase of approximately 2,806% compared to the average volume of 141 put options.
Henry Schein stock opened at $68.74 on Friday. The stock has a market capitalization of $10.04 billion, a P/E ratio of 16.64, a price-to-earnings-growth ratio of 2.62 and a beta of 0.85. Henry Schein has a 52 week low of $56.58 and a 52 week high of $72.81. The company has a debt-to-equity ratio of 0.30, a quick ratio of 0.95 and a current ratio of 1.63. The stock has a fifty day moving average of $63.06 and a 200-day moving average of $65.31.
Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings data on Tuesday, November 5th. The company reported $0.90 earnings per share for the quarter, topping analysts’ consensus estimates of $0.86 by $0.04. The business had revenue of $2.51 billion for the quarter, compared to analyst estimates of $2.52 billion. Henry Schein had a return on equity of 15.93% and a net margin of 4.66%. Henry Schein’s quarterly revenue was up 6.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.03 EPS. On average, research analysts forecast that Henry Schein will post 3.45 earnings per share for the current year.
In other news, Vice Chairman James P. Breslawski sold 6,856 shares of the firm’s stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $66.96, for a total transaction of $459,077.76. Following the sale, the insider now owns 242,190 shares of the company’s stock, valued at $16,217,042.40. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, SVP Michael S. Ettinger sold 3,671 shares of Henry Schein stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $66.96, for a total value of $245,810.16. Following the completion of the sale, the senior vice president now directly owns 87,972 shares in the company, valued at approximately $5,890,605.12. The disclosure for this sale can be found here. Company insiders own 1.06% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Enterprise Financial Services Corp boosted its position in Henry Schein by 101.3% during the 3rd quarter. Enterprise Financial Services Corp now owns 483 shares of the company’s stock valued at $31,000 after acquiring an additional 243 shares in the last quarter. Cullen Frost Bankers Inc. bought a new position in shares of Henry Schein during the 2nd quarter valued at about $36,000. Ibex Wealth Advisors bought a new position in shares of Henry Schein during the 2nd quarter valued at about $40,000. Meeder Asset Management Inc. purchased a new stake in shares of Henry Schein during the 2nd quarter valued at about $59,000. Finally, Rational Advisors LLC raised its position in shares of Henry Schein by 24.9% during the 2nd quarter. Rational Advisors LLC now owns 903 shares of the company’s stock valued at $63,000 after buying an additional 180 shares in the last quarter.
A number of equities research analysts recently issued reports on the company. BidaskClub lowered Henry Schein from a “hold” rating to a “sell” rating in a research report on Thursday, September 26th. Cleveland Research restated a “hold” rating on shares of Henry Schein in a research note on Friday, November 1st. Barrington Research restated a “buy” rating and issued a $75.00 price target on shares of Henry Schein in a research note on Wednesday. TheStreet upgraded Henry Schein from a “c+” rating to a “b” rating in a research note on Monday, October 14th. Finally, Zacks Investment Research downgraded Henry Schein from a “hold” rating to a “sell” rating and set a $71.00 price target for the company. in a research note on Wednesday. Six investment analysts have rated the stock with a sell rating, seven have issued a hold rating and four have issued a buy rating to the stock. Henry Schein presently has an average rating of “Hold” and an average target price of $73.50.
Henry Schein Company Profile
Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.
Further Reading: How Investors Use a Balance Sheet
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.